Major Depressive Disorder Clinical Trial
— FIDELIOOfficial title:
An Eight-week, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Study, With Escitalopram (10 mg Daily) as Active Control, to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Doses of SSR411298 (10, 50, or 200 mg Daily) in Elderly Patients With Major Depressive Disorder
Verified date | March 2013 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Russia: Ethics Committee |
Study type | Interventional |
The primary objective of this study is to evaluate the efficacy of 3 fixed doses of
SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major
Depressive Disorder (MDD), based on the 17-item Hamilton Depression Rating Scale.
Secondary objectives are:
- To evaluate the tolerability and safety of an 8-week treatment with SSR411298 versus
placebo in elderly patients with MDD.
- To evaluate the effect of SSR411298 on disability, anxiety, cognitive function, sleep,
pain and somatic symptoms related to depression, and bone markers.
- To assess SSR411298 plasma concentrations.
- To assess plasma endocannabinoid concentrations.
Status | Completed |
Enrollment | 527 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Elderly patient with recurrent Major Depressive Disorder Exclusion Criteria: - Duration of current depressive episode greater than 2 years; - Mild depression as measured by standard clinical research scales; - Cognitive disturbance; - Significant suicide risk; - Other psychiatric conditions that would obscure the results of the study; - History of failure to respond to antidepressant treatment. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Chile | Sanofi-Aventis Administrative Office | Santiago | |
Mexico | Sanofi-Aventis Administrative Office | Mexico | |
Romania | Sanofi-Aventis Administrative Office | Bucuresti | |
Russian Federation | Sanofi-Aventis Administrative Office | Moscow | |
Slovakia | Sanofi-Aventis Administrative Office | Brastislava | |
South Africa | Sanofi-Aventis Administrative Office | Midrand | |
Ukraine | Sanofi-Aventis Administrative Office | Kiev |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
Chile, Mexico, Romania, Russian Federation, Slovakia, South Africa, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 17-item Hamilton Depression Rating Scale (HAM-D) total score | The HAM-D consists of 17 items assessing signs and symptoms of depression. All items are scored with a severity rating from 0 (not present) to 2 or 4 (very severe), depending on the item. The minimum and maximum possible scores are 0 and 52, respectively. | 8 weeks (from D-1 (before randomization) up to D56) | No |
Secondary | Montgomery-Asberg Depression Rating Scale (MADRS) total score | The MADRS consists of 10 items assessing signs and symptoms of depression. All items are scored with a severity rating from 0 (not present) to 6 (most severe). The minimum and maximum possible scores are 0 and 60, respectively. | 8 weeks (from D-1 (before randomization) up to D56) | No |
Secondary | Clinical Global Impression (CGI) scores | The CGI-1 Severity of Illness score is rated on a 1 to 7 point scale. The CGI-2 Improvement score is a component of the CGI; the Improvement score captures the investigator's clinical impression regarding global improvement (or worsening) on a 7-point scale. |
D-1 (before randomization) and D56 | No |
Secondary | HAM-D depressed mood item score, factor scores and core item score | 8 weeks (from D-1 (before randomization) up to D56) | No | |
Secondary | Geriatric Depression Scale (GDS) total score | The GDS is a 15-item self report scale used to assess the more specific aspects of depression in elderly depressed patients. | D-1 (before randomization) and D56 | No |
Secondary | Sheehan Disability Scale (SDS) total score | The SDS contains 3 questions, which assesses interference in three domains, work and school, family life and home responsibilities, and social life. Each question is answered on a 10-point Likert Scale. | D-1 (before randomization) and D56 | No |
Secondary | Hamilton Anxiety Rating scale (HAM-A) total score | The HAM-A consists of 14 items assessing signs and symptoms of anxiety. All items are scored with a severity rating from 0 (not present) to 2 or 4 (very severe), depending on the item. The minimum and maximum possible scores are 0 and 56 respectively. | D-1 (before randomization) and D56 | No |
Secondary | Overview of Adverse Events (AE) | up to 9 weeks (from first study drug intake up to 7 days after last study drug intake) | Yes | |
Secondary | SSR411298 plasma concentration | Plasma concentrations of SSR411298 are determined by a validated liquid chromatography tandem mass spectrometry method with a lower limit of quantification of 10 ng/mL. | predose and 3-5 hours after study drug intake on Day 21 and Day 56 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |